High homogeneity of MMR deficiency in ovarian cancer.
CONCLUSIONS: Our data show that MSI is present in a substantial proportion of endometrioid ovarian cancers but can also occur in other tumor subtypes. MMR deficiency/MSI typically involves the entire tumor mass, suggesting that MMR inactivation occurs early in tumorigenesis in a subset of ovarian cancers. PMID: 31924330 [PubMed - as supplied by publisher]
Publication date: Available online 25 February 2020Source: Actas Urológicas Españolas (English Edition)Author(s): G. del Pozo Jiménez, F. Herranz Amo, J.A. Arranz Arija, E. Rodríguez Fernández, D. Subirá Ríos, E. Lledó García, G. Bueno Chomón, M.J. Cancho Gil, J. Carballido Rodríguez, C. Hernández Fernández
Publication date: Available online 25 February 2020Source: The American Journal of SurgeryAuthor(s): Kristen E. Limbach, SuEllen J. Pommier, Elizabeth Dewey, Enrique Leon, Rodney F. Pommier
Hi guys, I'm trying to gauge where I stand and am very confused due to my weird background. I took the MCAT in Jan and received a 524, but my GPAs are on the lower end. I am AA URM. GPA: 3.66c, 3.73s, 1 year 4.0 at end || 3.5 masters, 3.5 PhD first year (left see below) MCAT: 524 || Balanced, first take State: CA Race: URM, AA Clinical Volunteering: 250 hours - general hospital volunteer pulm unit 200 hours - driver for american cancer society patients 280... 3.66 cGPA, 3.73sGPA, 524 MCAT URM
Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Tony Kirby
Publication date: 2020Source: European Journal of Radiology Open, Volume 7Author(s): Anuradha Chandramohan, Umar M. Siddiqi, Rohin Mittal, Anu Eapen, Mark R. Jesudason, Thomas S. Ram, Ashish Singh, Dipti Masih
Publication date: 1 June 2020Source: Personality and Individual Differences, Volume 159Author(s): Donald H. Saklofske
Publication date: March 2020Source: Human Pathology: Case Reports, Volume 19Author(s): Van Chu Nguyen, Thi Huyen Phung, Tien Quang Nguyen, Phuong Hoa Nguyen Thi
GATA binding protein 3 (GATA3) immunohistochemistry is primarily used as a marker of breast and urothelial differentiation, particularly in metastatic settings. In the gynecologic tract it also serves a robust marker for mesonephric and trophoblastic tumors. However, expression has also been described in more common malignancies of gynecologic tract including ovarian, endometrial, and cervical carcinomas. Data on the distribution of GATA3 expression in gynecologic malignancies is somewhat limited, particularly across different histologic subtypes of ovarian, endometrial, and cervical carcinomas. To assess the rates of GATA...
Authors: Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M Abstract This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs a...